CTLA4 and neoplasm: In this second scenario, we have seen that both in naive tumor-free and in tumor-bearing mice, combination of vaccines (either OVA-CIRP or GPC3-CIRP) are more immunogenic in the presence of anti-CTLA-4 and anti-PD-1 antibodies.